Overview
The purpose of this document is to describe the guidelines Neighborhood Health Plan (NHP) uses to determine medical necessity for prostatic urethral lift (Urolift®).

Coverage Guidelines
NHP covers prostatic urethral lift in members with moderate-to-severe lower urinary tract obstruction (defined by American Urological Association [AUA] symptom score >7) due to benign prostatic hyperplasia (BPH) when ALL the following are met:

- The member has a diagnosis of BPH and symptoms are caused by enlargement of the median and/or lateral prostate lobes
- The member has persistent or progressive lower urinary tract symptoms despite medical therapy (alpha1-adrenergic antagonists, 5 alpha-reductase inhibitors, or combination medication therapy maximally titrated) over a trial period of no less than 6 months OR is unable to tolerate medical therapy
- Prostate gland volume is ≤80 cc
- Prostate anatomy demonstrates normal bladder neck without evidence of a stricture
- The member is poor candidate for other surgical procedures for BPH using general anesthesia, such as transurethral resection of the prostate

Exclusions
NHP does not provide coverage for prostatic urethral lift in the following instances:

1. The member has a contact dermatitis nickel allergy
2. The member has prostate-specific antigen level ≥3 ng/mL and has not had testing to exclude prostate cancer
3. The member has a urinary tract infection or recent prostatitis within the last year
4. The member has a urethral condition that may prevent insertion of delivery system into the bladder

Definitions
Prostatic Urethral Lift (PUL): The prostatic urethral lift (Urolift®) mechanically opens the prostatic urethra with implants that are placed transurethrally under cystoscopic visualization, thereby separating the encroaching prostatic lobes. The PUL is introduced into the urethra and used to compress the prostate tissue, thereby increasing the urethral lumen and reducing obstruction to urine flow. It is a minimally invasive, short endoscopic procedure that can be done under local, general, or regional anesthesia

Benign Prostatic Hyperplasia (BPH): Benign prostatic hyperplasia (BPH) is a common disorder among older individuals that results from hyperplastic nodules in the periurethral or transitional zone of the prostate. BPH prevalence increases with age and is present in more than 80% of individuals ages 70 to 79.
### CPT/HCPC Codes

<table>
<thead>
<tr>
<th>Authorized CPT/HCPCS Codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>52441</td>
<td>Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant</td>
</tr>
<tr>
<td>52442</td>
<td>Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>

**Effective**
September 2018: Effective date.

**References**

Cunningham G., Kadmon, D, et al. Transurethral procedures for treating benign prostatic hyperplasia. UpToDate. June 2018


